The CD200-mediated suppression was reversible when blocking the interaction with the CD200-receptor (CD200R) and a further study showed the benefit of a fully human CD200 antibody (TTI‐CD200), that improved immune responses to AML [71] indicating a therapeutic implication for relapsed AML patients. This evidence concerns the gene CD200 and acute myeloid leukemia.